Replies to post #55020 on Biotech Values

[mouton29]

"I really think this looks like a vehicle for shareholders / executives to milk a paycheck."

If we check that hypothesis generating theory by examining the CEO/major shareholders "paychecks," we find that they are zero and that he founded and funded the company with his own cash so he is net out of pocket a few million. Now at least Dew's theory -- that he took the company public so that he can sell stock to the unsuspected public shareholders -- is a possibility, even though he has not sold any yet.

I'm more interested in your view of the weakness of the science. I take it you think that the results in the two phase III Coprexa trials for Wilson's diseases were flukes or otherwise invalid notwithstanding their apparent success.

[Kadaicher1]

Gee PGS, that is a bit hard. "Companies that largely reformulate off-patent compounds aren't generally trustworthy or credible imo." I have a little cash invested in PRAN who have done just that. They have a 12 week trial on 80 alzheimers patients about to complete next month, so there are only a few months to wait for results. I think you will have to agree that if they see a strong trend to improved cognition in such a short trial, they may be credible. Yes? Although it has taken a year to enroll and complete all patients.

[rkrw]

Like Celgene? :-)

<<<<Companies that largely reformulate off-patent compounds aren't generally trustworthy or credible imo.>>>>

There was another company recently, Questcor, increased the price of their 50 year old (no joke) drug by 13 fold after it failed to get indicated for the same indication they get 99% of their sales (off label), infantile spasm. qsc went from 20 cents after the rejection to $5 after the first full quarter reflecting their new price. Missed that one.

I took a quick look at PP, the Wilson's Disease data for those with neurological impairment looks strong. Not sure if I'm missing something. Perhaps the strategy is to price it in the stratosphere. They make comments about ipf, but I couldn't find any real data anywhere, so most likely that's just bluster. In any case, perhaps various other indications are bs, write them down to zero, but what of Wilson's, what's the potential sales there? I have no clue.